-
Something wrong with this record ?
Identification of inhibitors regulating cell proliferation and FUS-DDIT3 expression in myxoid liposarcoma using combined DNA, mRNA, and protein analyses
D. Svec, S. Dolatabadi, C. Thomsen, N. Cordes, M. Shannon, P. Fitzpatrick, G. Landberg, P. Åman, A. Ståhlberg,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Free Medical Journals
from 2000 to 1 year ago
ProQuest Central
from 2000-01-01 to 2022-12-31
Open Access Digital Library
from 2000-01-01
Open Access Digital Library
from 2000-01-01
Health & Medicine (ProQuest)
from 2000-01-01 to 2022-12-31
Public Health Database (ProQuest)
from 2000-01-01 to 2022-12-31
- MeSH
- DNA analysis genetics metabolism MeSH
- Oncogene Proteins, Fusion analysis genetics metabolism MeSH
- Humans MeSH
- RNA, Messenger analysis genetics metabolism MeSH
- Liposarcoma, Myxoid genetics metabolism MeSH
- Cell Line, Tumor MeSH
- Cell Proliferation drug effects MeSH
- Antineoplastic Agents pharmacology MeSH
- Gene Expression Regulation, Neoplastic drug effects MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
FUS-DDIT3 belongs to the FET (FUS, EWSR1, and TAF15) family of fusion oncogenes, which collectively are considered to be key players in tumor development. Even though over 90% of all myxoid liposarcomas (MLS) have a FUS-DDIT3 gene fusion, there is limited understanding of the signaling pathways that regulate its expression. In order to study cell proliferation and FUS-DDIT3 regulation at mRNA and protein levels, we first developed a direct cell lysis approach that allows DNA, mRNA, and protein to be analyzed in the same sample using quantitative PCR, reverse transcription quantitative qPCR and proximity ligation assay, respectively. We screened 70 well-characterized kinase inhibitors and determined their effects on cell proliferation and expression of FUS-DDIT3 and FUS at both mRNA and protein levels in the MLS 402-91 cell line, where twelve selected inhibitors were evaluated further in two additional MLS cell lines. Both FUS-DDIT3 and FUS mRNA expression correlated with cell proliferation and both transcripts were co-regulated in most conditions, indicating that the common 5' FUS promotor is important in transcriptional regulation. In contrast, FUS-DDIT3 and FUS protein levels displayed more cell line dependent expression. Furthermore, most JAK inhibitors caused FUS-DDIT3 downregulation at both mRNA and protein levels. In conclusion, defining factors that regulate FUS-DDIT3 expression opens new means to understand MLS development at the molecular level.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19028496
- 003
- CZ-PrNML
- 005
- 20190823092835.0
- 007
- ta
- 008
- 190813s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41374-018-0046-3 $2 doi
- 035 __
- $a (PubMed)29588491
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Svec, David $u Sahlgrenska Cancer Center, Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Medicinaregatan 1F, 413 90, Gothenburg, Sweden. Laboratory of gene expression, Institute of Biotechnology AS CR, BIOCEV, Prumyslova 595, 252 50, Vestec by Prague, Czech Republic.
- 245 10
- $a Identification of inhibitors regulating cell proliferation and FUS-DDIT3 expression in myxoid liposarcoma using combined DNA, mRNA, and protein analyses / $c D. Svec, S. Dolatabadi, C. Thomsen, N. Cordes, M. Shannon, P. Fitzpatrick, G. Landberg, P. Åman, A. Ståhlberg,
- 520 9_
- $a FUS-DDIT3 belongs to the FET (FUS, EWSR1, and TAF15) family of fusion oncogenes, which collectively are considered to be key players in tumor development. Even though over 90% of all myxoid liposarcomas (MLS) have a FUS-DDIT3 gene fusion, there is limited understanding of the signaling pathways that regulate its expression. In order to study cell proliferation and FUS-DDIT3 regulation at mRNA and protein levels, we first developed a direct cell lysis approach that allows DNA, mRNA, and protein to be analyzed in the same sample using quantitative PCR, reverse transcription quantitative qPCR and proximity ligation assay, respectively. We screened 70 well-characterized kinase inhibitors and determined their effects on cell proliferation and expression of FUS-DDIT3 and FUS at both mRNA and protein levels in the MLS 402-91 cell line, where twelve selected inhibitors were evaluated further in two additional MLS cell lines. Both FUS-DDIT3 and FUS mRNA expression correlated with cell proliferation and both transcripts were co-regulated in most conditions, indicating that the common 5' FUS promotor is important in transcriptional regulation. In contrast, FUS-DDIT3 and FUS protein levels displayed more cell line dependent expression. Furthermore, most JAK inhibitors caused FUS-DDIT3 downregulation at both mRNA and protein levels. In conclusion, defining factors that regulate FUS-DDIT3 expression opens new means to understand MLS development at the molecular level.
- 650 _2
- $a protinádorové látky $x farmakologie $7 D000970
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a proliferace buněk $x účinky léků $7 D049109
- 650 _2
- $a DNA $x analýza $x genetika $x metabolismus $7 D004247
- 650 _2
- $a regulace genové exprese u nádorů $x účinky léků $7 D015972
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a myxoidní liposarkom $x genetika $x metabolismus $7 D018208
- 650 _2
- $a fúzní onkogenní proteiny $x analýza $x genetika $x metabolismus $7 D015514
- 650 _2
- $a messenger RNA $x analýza $x genetika $x metabolismus $7 D012333
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Dolatabadi, Soheila $u Sahlgrenska Cancer Center, Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Medicinaregatan 1F, 413 90, Gothenburg, Sweden.
- 700 1_
- $a Thomsen, Christer $u Sahlgrenska Cancer Center, Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Medicinaregatan 1F, 413 90, Gothenburg, Sweden.
- 700 1_
- $a Cordes, Nicole $u Sahlgrenska Cancer Center, Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Medicinaregatan 1F, 413 90, Gothenburg, Sweden.
- 700 1_
- $a Shannon, Mark $u Genetic Sciences Division, Thermo Fisher Scientific, 180 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
- 700 1_
- $a Fitzpatrick, Paul $u Sahlgrenska Cancer Center, Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Medicinaregatan 1F, 413 90, Gothenburg, Sweden.
- 700 1_
- $a Landberg, Göran $u Sahlgrenska Cancer Center, Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Medicinaregatan 1F, 413 90, Gothenburg, Sweden.
- 700 1_
- $a Åman, Pierre $u Sahlgrenska Cancer Center, Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Medicinaregatan 1F, 413 90, Gothenburg, Sweden.
- 700 1_
- $a Ståhlberg, Anders $u Sahlgrenska Cancer Center, Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Medicinaregatan 1F, 413 90, Gothenburg, Sweden. anders.stahlberg@gu.se. Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden. anders.stahlberg@gu.se. Department of Clinical Pathology and Genetics, Sahlgrenska University Hospital, 413 45, Gothenburg, Sweden. anders.stahlberg@gu.se.
- 773 0_
- $w MED00003111 $t Laboratory investigation; a journal of technical methods and pathology $x 1530-0307 $g Roč. 98, č. 7 (2018), s. 957-967
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29588491 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20190823093050 $b ABA008
- 999 __
- $a ok $b bmc $g 1433645 $s 1066956
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 98 $c 7 $d 957-967 $e 20180327 $i 1530-0307 $m Laboratory investigation $n Lab Invest $x MED00003111
- LZP __
- $a Pubmed-20190813